Biomea Fusion, Inc.

NasdaqGS BMEA

Biomea Fusion, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -149.62 M

Biomea Fusion, Inc. EBITDA is USD -149.62 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -31.47% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Biomea Fusion, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -113.81 M, a -59.32% change year over year.
Biomea Fusion, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -71.44 M, a -135.57% change year over year.
Biomea Fusion, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -30.32 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: BMEA

Biomea Fusion, Inc.

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road
Employees	107
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years